Sagimet Biosciences Inc. (NASDAQ: SGMT) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT SAGIMET BIOSCIENCES INC.

Sagimet Biosciences Inc. (NASDAQ: SGMT)
Listen to this Section


$6.97
+0.1100 ( +1.60% ) 201.0K

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Clinical Trial Pipeline Stages


Drug Name Stage
Denifanstat w/ BevacizumabDetailsGlioblastoma Phase 3
Denifanstat (ASC40)DetailsAcne Phase 3
DenifanstatDetailsNon-alcoholic steatohepatitis Phase 3
DenifanstatDetailsLiver disease Phase 1

Market Data


Open $6.97
Previous Close $6.86
Volume 201.0K
Market Cap $423.62M
Day Range $6.83 - $7.25
52 Week Range $3.83 - $11.41
Shares Outstanding 61.75M
Change % +1.60%
Net Change ▲ 0.1100
Insider Ownership -0.02%
Exchange NASDAQ
SectorHealthcare
Industry
IPO Year2023
CountryUnited States
UnderwriterGoldman Sachs, TD Cowen, Piper Sandler, Citizens JMP, more

Insider Ownership Transactions

Total Amount Purchased: -6,468,882.00

Date Type Amount Purchased Purchaser
2024-08-05 Sale -113895.00 Jarrett Jennifer
2024-08-05 Sale -113895.00 Phillips Anne M.
2024-07-25 Sale -23625.00 Kemble George
2024-07-23 Sale -8357.00 Martins Eduardo Bruno
2024-07-23 Sale -10914.00 Rozek Elizabeth
2024-07-23 Sale -14062.00 Kemble George
2024-06-07 Sale -51459.00 SEIDENBERG BETH C
2024-06-07 Sale -51459.00 Parsey Merdad
2024-06-07 Sale -9279.00 Walbert Timothy P
2024-06-07 Sale -9279.00 Hoelscher Paul W.

SEC Filings


Form Type Description Pages Date
schedule Other 1 Nov 14, 2025
8-k 8K-related 66 Nov 13, 2025
10-q Quarterly Reports 55 Nov 13, 2025
4 Insider transactions 1 Nov 06, 2025
8-k 8K-related 64 Oct 23, 2025
8-k 8K-related 13 Aug 22, 2025
8-k 8K-related 15 Aug 14, 2025
10-q Quarterly Reports 62 Aug 13, 2025
8-k 8K-related 65 Aug 13, 2025
4 Insider transactions 1 Jul 23, 2025

Latest News


× Before browsing our site, please accept our cookies policy